David Marek, Myovant
Myovant beefs up data package in NDA #3, boosting its case for longterm dosing of Pfizer-partnered relugolix
When Pfizer handed over $650 million in cash to partner on Myovant’s relugolix, the pharma giant made clear that the deal — valued at $4.2 billion total — was just as much about the approved indication of prostate cancer as the two women’s health conditions the drug could treat.
A month later, the two companies are offering another glimpse of the therapy’s longterm potential in endometriosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
